Skip to main content
. 2019 Nov 6;19:1054. doi: 10.1186/s12885-019-6304-y

Table 1.

Characteristics of the identified guidelines on management of NMIBC

Guideline ID Target disease Development organization Version Country Funding Pages
The edition The type
ESMO, 2014 [8] BC European Society for Medical Oncology, ESMO The second Full version Europe Not reported 9
NICE, 2015 [9] BC National Institute for Health and Care Excellence, NICE The first

Full version;

NICE version;

NICE pathways;

Information for the Public (IFP)

U.K. NICE 500
CUA, 2015 [10] NMIBC Canadian Cancer Society, CUA The second Full version Canada Not reported 15
AUA/SUO, 2016 [3] NMIBC American Urological Association, AUA/Society of Urologic Oncology, SUO The first Full version America AUA 45
JUA, 2016 [11] BC Japanese Urological Association, JUA The second Full version Japan JUA 6
EAU, 2018 [12] NMIBC European Association of Urology, EAU Updated annually

Full version;

Pocket guideline;

Translated version

Europe EAU 48
ICUD/SIU, 2018 [13] NMIBC International Consultation on Urological Diseases, ICUD/Société Internationale d’Urologie, SIU The fifth Full version International Not reported 10
CRHA/CPAM, 2018 [14] NMIBC Chinese Research Hospital Association, CRHA/China International Exchange and Promotive Association for Medical and Health Care, CPAM The first Simplified version China

The National Key Research and Development Program of China;

Health and Family Planning Commission of Hubei province joint funding project

6
NCCN, 2019 [15] BC National Comprehensive Cancer Network, NCCN Updated every few months Full version America Not reported 103